Clinical trials: Metabolic Disease
ALS (Amyotrophic Lateral Sclerosis)
Intermediate-size Patient Population Expanded Access Protocol
The purpose of this Expanded Access Program is to provide tazbentetol to ALS patients who are not eligible to enroll in an ALS clinical trial.
- Trial name
- NCT07088159
- Testing
- Tazbentetol
- Where
- 16 sites in United States
- Sponsor
- Spinogenix
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis
To evaluate the efficacy of fasiglifam 50 mg once daily compared to placebo on glycemic control as measured by glycosilated haemoglobin (HbA1c) over a 16-week treatment period in participants with Type 2 Diabetes Mellitus (T2DM)…
- Trial name
- NCT02015780
- Testing
- Fasiglifam, Antihyperglycemic therapy
- Where
- 30 sites in United States, Bulgaria and 5 more
- Sponsor
- Takeda
Postmenopausal Osteoporosis
Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)
This was an open-label, single-center study to evaluate the usability of abaloparatide-sMTS by participants with low BMD.
- Trial name
- NCT04366726
- Testing
- abaloparatide-sMTS
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Radius Health, Inc.
Diabetes Mellitus, Type 2
Digital Diabetes Remission Trial
This is a multicentre, open-label Randomised Controlled Trial run in the United Kingdom. The main aims are to assess whether the Habitual Remission Programme (digital therapeutics + 12-week 800kcal/day low-energy diet, delivered…
- Trial name
- DIGEST (NCT05647226)
- Testing
- Digital therapeutic and intensive lifestyle programme, Standard of care
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Habitual Health Ltd
Diabetes Mellitus Progression, Diabetes Complications
Autologous Bone Marrow Transplant in Chronic Insulin Dependent Diabetic Patients
Diabetes, recently declared a pandemic by the World Health Organization, is a risk factor for increased mortality and morbidity.
- Trial name
- NCT03562208
- Testing
- Adult Bone Marrow Stem Cells
- Where
- The Bahamas
- Volunteers
- 100 people
- Sponsor
- Global Cell Med
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
- Conditions
- Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma
- Trial name
- NCT06805825
- Testing
- NN3201
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Novelty Nobility, Inc.
Obesity, Insulin Resistance
The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects
The primary objective of this study is to determine whether MICARDIS® improves insulin sensitivity in overweight or obese, non-diabetic, normotensive subjects.
- Trial name
- NCT00146289
- Testing
- MICARDIS® (telmisartan)
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 138 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus"
The purpose of this survey is to evaluate the long-term safety and efficacy of trelagliptin tablets in patients with type 2 diabetes mellitus in the routine clinical setting.
- Trial name
- NCT03555591
- Testing
- Trelagliptin
- Where
- Japan
- Volunteers
- 3,198 people
- Sponsor
- Takeda
Diabetes Mellitus, Coronary Artery Disease
Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)
This trial is designed as a phase 2 randomized, double-blind double dummy, active comparator controlled, two-period two-arm crossover study to enroll 40 patients across multiple centers.
- Trial name
- OPTIMUS-3 (NCT00642174)
- Testing
- prasugrel, Clopidogrel
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Hypercholesterolemia
MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)
This study is to assess the safety and efficacy of an investigational drug as compared to an approved drug to reduce specific cholesterol levels.
- Trial name
- NCT00092690
- Testing
- MK0653A, ezetimibe (+) simvastatin, Comparator: atorvastatin
- Volunteers
- 1,902 people
- Sponsor
- Organon and Co
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
A Phase 2b Study of Zagociguat in Patients With MELAS
PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs.
- Trial name
- PRIZM (NCT06402123)
- Testing
- zagociguat 15mg, zagociguat 30mg
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 43 people
- Sponsor
- Tisento Therapeutics
Dyslipidemia
12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia
The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia
- Trial name
- NCT00664859
- Testing
- LCP-AtorFen
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Veloxis Pharmaceuticals
Type 2 Diabetes Mellitus
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients
This study is to evaluate the efficacy and safety after concomitant administration of ASP1941 and sulfonylurea in patients with diabetes mellitus.
- Trial name
- NCT01242215
- Testing
- ipragliflozin, Sulfonylurea
- Where
- 7 sites in Japan
- Volunteers
- 243 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes
A Relative Bioavailability Study of HRS9531 in Healthy Subjects
The purpose of this study is to evaluate the relative bioavailability of the new formulation of HRS9531 injection between the original formulation of HRS9531 injection.
- Trial name
- NCT05893576
- Testing
- HRS9531
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Erectile Dysfunction
Therapeutic Effectiveness of Vardenafil in Patients With Erectile Dysfunction and Metabolic Syndrome in Daily Clinical Practice
The primary goal of this international non-interventional study is to investigate the therapeutic effectiveness of vardenafil (film-coated tablet) in Erectile Dysfunction patients with the Metabolic Syndrome in daily clinical…
- Trial name
- REVITALISE (NCT01106118)
- Testing
- Vardenafil (Levitra, BAY38-9456)
- Where
- 10 sites in Egypt, Israel and 8 more
- Volunteers
- 2,289 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.
- Trial name
- NCT01300260
- Testing
- LY2189265, Insulin, Glucose
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hypertension
Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults
The purpose of this study is to compare the blood pressure lowering efficacy of valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of obese hypertensive (mean sitting systolic blood pressure…
- Trial name
- NCT00439738
- Testing
- HCTZ + Amlodipine, Valsartan/HCTZ
- Where
- 5 sites in United States
- Volunteers
- 412 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis
Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension
This study provides an opportunity for subjects in the REFALS (3119002; NCT03505021) study to continue treatment with oral levosimendan.
- Trial name
- REFALS-ES (NCT03948178)
- Testing
- Levosimendan
- Where
- 79 sites in United States, Australia and 12 more
- Volunteers
- 227 people
- Sponsor
- Orion Corporation, Orion Pharma
Diabetes, Diabetes Mellitus, Type 2
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Europe and North America. The aim of this trial is to compare the effect on blood sugar control of liraglutide or sitagliptin, both in combination with metformin, in subjects with type 2 diabetes…
- Trial name
- NCT00700817
- Testing
- liraglutide, sitagliptin, metformin
- Where
- 166 sites in United States, Canada and 13 more
- Volunteers
- 665 people
- Sponsor
- Novo Nordisk A/S
Parkinson's Disease
The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.
The purpose of this study is to test whether Rifampin affects blood levels of istradefylline in humans. Rifampin could possibly decrease istradefylline levels.
- Trial name
- NCT02174250
- Testing
- Istradefylline 40 mg, Rifampin 300mg BID + istradefylline 40mg Day 8 only
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.